SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

ANVS

Annovis Bio Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed3d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The March 2027 DUET-AD topline data is the primary catalyst; the $21M raise provides runway to that event but leaves no margin for delay. Monitor enrollment close of OLE-PD (Jan 29, 2027) and any early signals from CTAD presentations Nov 16-19.

DirectionNeutral
Confidencehigh
Horizonmonths

buntanetap

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 Alzheimer's succeeds, NDA submission could come in early 2027 (symptomatic) or early 2028 (disease-modifying). Earliest potential FDA approval would be late 2028 at best.
Next catalyst
None dated

What to watchInvestors should watch for the Q1 2027 Alzheimer's Phase 3 symptomatic readout as the defining catalyst. The company will likely need additional financing before then given ~$14M cash and ~$17M/quarter burn. The Parkinson's miss on ITT primary endpoint is a cautionary precedent. Analyst consensus is strong-buy with $11 mean PT, but that reflects binary-option-like upside rather than de-risked fundamentals.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9261
T+0 close · Nov 13, 2026 · via day close
Latest settled
−19.02%
T+1 · $0.7500
Vs SPY
−17.10%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.9261entry
  2. T+1 · 21h ago −19.02%α −17.10% · $0.7500
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio reported a Q3 2026 net loss of $0.22 per share, narrower than the $0.37 loss in Q3 2025, but the company ended the quarter with only $2.8M cash, down from $19.5M at year-end 2025. The company raised $21M in a dilutive offering on Nov 6 to fund operations through the March 2027 DUET-AD Phase 3 data readout, which is the key catalyst.

Key Financial Metrics

EPS
−$0.22

Key Facts

  • Q3 2026 net loss $9.5M vs $7.3M in Q3 2025; basic EPS -$0.22 vs -$0.37
  • Cash and equivalents $2.8M at Sept 30, 2026, down from $19.5M at Dec 31, 2025
  • Raised $21M gross in Nov 6 offering; chairman contributed $5M
  • DUET-AD Phase 3 trial fully enrolled (862 patients); 6-month data readout expected March 2027
  • R&D expenses $15.8M in Q3 2026 vs $6.3M in Q3 2025, reflecting trial execution costs
  • 42.7M shares outstanding at Sept 30, 2026, up from 27.2M at Dec 31, 2025

Financial Impact

Cash burn of ~$16.7M in Q3 2026; $21M offering extends runway to March 2027 data readout

cashdilutionnet loss

Risk Factors

  • Cash runway only extends to March 2027 data readout; any delay in results or need for additional trials would require further dilutive financing
  • Massive share dilution (42.7M shares vs 27.2M at year-end 2025) and additional warrants outstanding
  • NYSE delisting risk from prior non-compliance notice remains
  • Phase 3 data readout is binary; failure would likely render equity worthless

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402540

Track record

19 reports on ANVS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.53% at T+20 after the May 20, 2026 report. 4 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 5/10 Viewing Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
  2. Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
  3. Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
  4. Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
  5. Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
  6. Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
  7. Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
  8. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
  9. Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
  10. Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
Showing 10 of 19

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026